Well-versed in regulation
25.07.2016 - Swedish rare disease expert Wilson Therapeutics AB has appointed global regulatory executive Rick Lilley as Chief Regulatory Officer.
Lilley, who received his BSc in microbiology and genetics as well as his PhD in molecular genetics from Queen Mary College, University of London, has held senior positions in regulatory affairs and drug development in Europe, Japan and USA for the last three decades. Most recently, he served as Senior VP and Head of Global Regulatory Affairs at US pharma company Vertex Pharmaceuticals. At Vertex, he was responsible for the global filings for the breakthrough orphan drug Orkambi. Prior to that, Lilley was VP and Head of Global Regulatory Affairs at Belgian biopharma UCB. He has also held senior regulatory positions at Johnson & Johnson, Shire and AstraZeneca.http://www.european-biotechnology-news.com/people/bio-people/2016/rick-lilley.html